Impact of the COVID-19 Pandemic on Outcomes and Perioperative Factors Associated with Posterior Cervical Fusion

Alex Ngan¹, Junho Song¹, Austen Katz¹, Sarah Trent¹, Priya Duvvuri¹, John Fallon¹, Anas Abbas¹, Terence Ng¹, David Essig¹, Jeff Silber¹, Sohrab Virk¹

Northwell Health

Alexngan93@gmail.com

Disclosures: None

INTRODUCTION: While there is anecdotal evidence that the pandemic altered perioperative decision-making in patients requiring PCF, there has not yet been a national-level analysis performed to examine the significance of this hypothesis. This study aimed to evaluate for potential differences in perioperative variables and surgical outcomes of posterior cervical fusion (PCF) performed before vs. during the coronavirus-19 pandemic.

METHODS: Adults who underwent PCF were identified in the 2019 (pre-pandemic) and 2020 (intra-pandemic) NSQIP datasets. Differences in 30-day readmission, reoperation, and morbidity were evaluated for using multivariate logistic regression. Differences in operative time and relative value units (RVUs) were estimated via quantile regression. Odds ratios for length of stay (LOS) were estimated via negative binomial regression. Secondary outcomes included rates of non-home discharge and outpatient surgery.

RESULTS SECTION: There were 3,444 patients (50.7% from 2020). Readmission, reoperation, morbidity, operative time, and RVUs per minute were similar between cohorts. LOS and RVUs per case were significantly greater in 2020. Operation year 2020 independently predicted lower rates of non-home discharge and greater rates of outpatient surgery.

DISCUSSION: During the COVID-19 pandemic, there was 28% decreased odds of nonhome discharge following PCF and 72% increased odds of PCF being performed in an outpatient setting. Rates of readmission, reoperation, and morbidity remained unchanged during this period. This is notable given that patients in the 2020 group were more medically frail.

SIGNIFICANCE/CLINICAL RELEVANCE: This suggests that patients were shifted to outpatient centers, possibly to make up for potentially reduced case volume, which highlights the potential to evaluate rehabilitation-discharge criteria. Further research should evaluate these findings in more detail and on a regional basis.

IMAGES AND TABLES:

30-day outcomes	OR (95% CI)	<i>p</i> -value	
Readmission	0.968 (0.736, 1.271)	0.813	
Reoperation	0.801 (0.548, 1.170)	0.251	
Morbidity	0.915 (0.711, 1.177)	0.489	
Perioperative variables	OR (95% CI)	<i>p</i> -value	
Length of stay (days)	1.086 (1.037, 1.136)	< 0.001	
Perioperative variables	Coefficient (95% CI)	<i>p</i> -value	
RVUs per minute	0.004 (-0.011, 0.020)	0.589	
RVUs per case	0.360 (0.021, 0.699)	0.037	
Operative time (min)	1.481 (-4.292, 7.254)	0.615	

Bold values indicate statistical significance (p<0.05). OR, odds ratio. CI, confidence interval. SSI, surgical site infection.

	2019 N(%)	2020 N (%)	<i>p</i> -value	
	N=1,699	N=1,745		
30-day outcomes				
Readmission	122 (7.2%)	124 (7.1%)	0.932	
Reoperation	70 (4.1%)	63 (3.6%)	0.438	
Morbidity	167 (9.8%)	179 (10.3%)	0.676	
Complications				
Superficial SSI	28 (1.6%)	23 (1.3%)	0.423	
Deep SSI	7 (0.4%)	12 (0.7%)	0.275	
Organ/Space SSI	13 (0.8%)	11 (0.6%)	0.635	
Wound disruption	12 (0.7%)	14 (0.8%)	0.745	
Pneumonia	13 (0.8%)	17 (1.0%)	0.509	
Unplanned intubation	11 (0.6%)	7 (0.4%)	0.316	
Pulmonary embolism	13 (0.8%)	14 (0.8%)	0.902	
Ventilator >48 hours	4 (0.2%)	4 (0.2%)	1.000#	
Renal insufficiency	4 (0.2%)	1 (0.1%)	0.212#	
Acute renal failure	2 (0.1%)	1 (0.1%)	0.620#	
Urinary tract infection	24 (1.4%)	28 (1.6%)	0.644	
Stroke	3 (0.2%)	4 (0.2%)	1.000#	
Cardiac arrest requiring CPR	3 (0.2%)	4 (0.2%)	1.000#	
Myocardial infarction	8 (0.5%)	10 (0.6%)	0.678	
Transfusion	49 (2.9%)	53 (3.0%)	0.791	
Deep venous thrombosis	18 (1.1%)	11 (0.6%)	0.168	
Sepsis	19 (1.1%)	10 (0.6%)	0.080	
Perioperative outcomes				
Operative time (min; median, IQR)	155 (117-208)	159 (118-207)	0.723	
RVUs per minute (median, IQR)	0.36 (0.24-0.49)	0.36 (0.26-0.49)	0.558	
RVUs per case (median, IQR)	57.8 (48.8-65.3)	57.8 (51.3-65.1)	0.127	
Length of stay (days; mean + SD)	4.0 (3.2)	4.2 (3.5)	0.015	

	2019 N (%)	2020 N (%)	p-value
Demographics	N=1,699	N=1,745	
Age (years), mean ± SD	63.9 (10.1)	64.2 (10.7)	0.175
Female sex	735 (43.3%)	682 (39.1%)	0.013
Non-white race	279 (19.1%)	344 (22.9%)	0.012
Hispanic ethnicity	114 (7.7%)	133 (8.5%)	0.385
Comorbidities			
5-item modified frailty index	T		
mFI-5=0	538 (31.7%)	513 (29.5%)	0.159
mFI-5 = 1	759 (44.7%)	722 (41.4%)	0.051
mFI-5 \geq 2	402 (23.7%)	509 (29.2%)	< 0.001
BMI	30.1 (6.4)	30.0 (6.5)	0.399
Diabetes mellitus	393 (23.1%)	460 (26.4%)	0.028
Dyspnea	125 (7.4%)	125 (7.2%)	0.826
Functional dependence	77 (4.6%)	82 (4.7%)	0.836
Smoker	356 (21.0%)	402 (23.0%)	0.140
COPD	101 (5.9%)	124 (7.1%)	0.168
Congestive heart failure	9 (0.5%)	8 (0.5%)	0.765
Hypertension requiring medication	1,034 (60.9%)	1,132 (64.9%)	0.015
Chronic steroid use	93 (5.5%)	75 (4.3%)	0.109
Bleeding disorder	19 (1.1%)	27 (1.5%)	0.273
ASA class ≥3	1,147 (67.5%)	1,221 (70.0%)	0.119
Laboratory values			
Creatinine	0.96 (0.54)	1.01 (0.73)	0.056
White cell count	7.4 (2.5)	7.4 (2.5)	0.989
Hematocrit	41.5 (4.5)	41.3 (4.8)	0.175
Platelet count	247 (73)	245 (71)	0.357
Procedural factors			
Nonhome discharge	438 (25.8%)	389 (22.3%)	0.017
Outpatient surgery	51 (3.0%)	84 (4.8%)	0.006
4+ levels fused	260 (15.3%)	270 (15.5%)	0.890